Value of Cortactin Expression in Invasive and Non-invasive Urinary Bladder Urothelial Carcinoma in Egyptian Population

NCT05070039 | Completed DMC

• 1 other identifier: Soh-Med-21-09-44
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

Urothelial carcinoma is the ninth most common malignant neoplasm worldwide. nearly in all human tumors, actin filaments are involved in lamellopodia or cellular extensions. Cortactin is involved in fixing the actin assembly to enhance cellular penetration. Assessment of Cortactin expression in invasive and non-invasive urothelial carcinoma and recording any significant different expressions may have benefits in developing more effective anticancer chemotherapeutic agents.

Conditions

Urothelial Carcinoma

Keywords

Cortactin; Urothelial carcinoma

Outcome Measures

Primary Outcomes (1)

• Assessment and correlating Cortactin expression in invasive and non-invasive urothelial carcinoma.

  immunohistochemical staining of tumor sections and correlating the immuno-expresion of Cortactin to different tumor parameters as tumor grade, stage and status of lymph nodes involved, inorder to detect the prognostic role of Cortactin in urothelial carcinoma.

  6 months

Study Arms (1)

patients with invasive and non invasive urothelial carcinoma

OTHER

patients with urothelial carcinoma will be subjected to radical cystectomy or trans uretheral resection of the tumor, specimens will be sent to the pathology lab. to be examined.

Genetic: Expression of Cortactin anti body

Interventions

Expression of Cortactin anti body GENETIC

assessment of Cortactin immunohistochemical expression in invasive and non-invasive urothelial carcinoma.

patients with invasive and non invasive urothelial carcinoma

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• patients with primary urinary bladder carcinoma.

You may not qualify if:

• patients received chemotherapeutic agents.

Sponsors & Collaborators

• Sohag University: lead

Study Sites (1)

Maisa Hashem Mohammed

Sohag, 82524, Egypt

Location

MeSH Terms

Conditions

Carcinoma, Transitional Cell

Condition Hierarchy (Ancestors)

Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: lecturer of pathology

Model Details: formalin fixed and paraffin embedded blocks of urinary bladder malignant neoplasms will be obtained and sectioned. from each block, one tissue section will be stained by H\&E, other section will be stained immunohistochemically by anti Cortactin antibodies.

Study Record Dates

• First Submitted: September 19, 2021
• First Posted: October 6, 2021
• Study Start: July 1, 2021
• Primary Completion: December 30, 2021
• Study Completion: January 1, 2022
• Last Updated: July 15, 2022

Record last verified: 2022-07

Data Sharing

• IPD Sharing: Will not share

Locations

EG (1)